Adolor Corp. reported topline results from a Phase III study showing its postoperative ileus drug, alvimopan, failed to meet the primary endpoint in a trial meant to support a marketing authorization application in the European Union. (BioWorld Today)
Just a few weeks after completing the treatment portion of a Phase II/III trial of Fibrillex, Neurochem Inc. partnered its AA amyloidosis drug with Centocor Inc. in a deal worth up to $54 million. (BioWorld Today)
Arena Pharmaceuticals Inc. takes a case-by-case approach when it comes to partnering its drug candidates. If the economics are right, the San Diego-based company will sign on the dotted line. (BioWorld Today)
Aphton Corp. entered a definitive agreement to acquire the privately held Vienna, Austria-based company Igeneon AG for more than $81 million in equity. (BioWorld Today)
With slower-than-expected sales growth of Bexxar, Corixa Corp. decided to turn worldwide rights for the non-Hodgkin's lymphoma product over to partner GlaxoSmithKline plc. (BioWorld Today)
